High expression of CXCL13 is predictive of better survival in HR+/HER2− breast cancer patients treated with adjuvant chemotherapy36, and is associated with higher pathologic complete response rate after neoadjuvant chemotherapy in HR+ breast cancers17. This evidence concerns the gene CXCL13 and breast carcinoma.